Format

Send to

Choose Destination
Curr Eye Res. 2015;40(11):1153-65. doi: 10.3109/02713683.2014.987870. Epub 2014 Dec 11.

Synergistic Effect of Curcumin in Combination with Anticancer Agents in Human Retinoblastoma Cancer Cell Lines.

Author information

1
a L&T Department of Ocular Pathology , Vision Research Foundation , Sankara Nethralaya, Nungambakkam , Chennai , Tamil Nadu , India and.
2
b Birla Institute of Technology & Science (BITS) Scholar , Pilani , Rajasthan , India.

Abstract

PURPOSE:

Curcumin (diferuloylmethane), a phenolic compound obtained from the rhizome of the herb Curcuma longa, is known to have anti-proliferative and anti-tumor properties. In this study, we evaluated the cytotoxic effect of curcumin alone and in combination with individual drugs like carboplatin, etoposide, or vincristine in a human retinoblastoma (RB) cancer cell line.

MATERIALS AND METHODS:

A drug-drug interaction was analyzed using the median effect/isobologram method and combination index values were used to characterize the interaction as synergistic or additive. We also performed the apoptosis and cell-cycle kinetics study with single drugs in combination with curcumin in a human RB cell lines (Y79 and Weri-Rb1).

RESULTS:

Curcumin caused concentration-dependent decrease in cell proliferation, cell kinetics, and also induced apoptosis in both the RB cell lines. When combination of curcumin with individual drugs like carboplatin or etoposide or vincristine was treated on to RB cells, both cell viability and cell cycling were reduced and increased apoptosis was noted, in comparison with single drug treatment. These effects were significant in both the cell lines, indicating the ability of curcumin to increase the sensitivity of RB cells to chemotherapy drugs.

CONCLUSION:

Our in vitro findings showed that the combination of curcumin with single drug treatment showed marked synergistic inhibitory effect against RB cell lines. These results suggest that curcumin can be used as a modulator which may have a potential therapeutic value for the treatment of RB cancer patients.

KEYWORDS:

Additive; chemotherapy drugs; combination index; curcumin; isobologram; retinoblastoma; synergistic

PMID:
25495096
DOI:
10.3109/02713683.2014.987870
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center